Pfizer (PFE) Other Non-Current Assets (2009 - 2026)

Pfizer has disclosed Other Non-Current Assets across 18 years of filings, most recently posting $9.8 billion for Q1 2026.

• In Q1 2026, Other Non-Current Assets changed 0.11% year-over-year to $9.8 billion; the TTM figure through Mar 2026 stood at $9.8 billion (changed 0.11% YoY), while the FY2025 annual figure was $9.6 billion, down 1.89% from the prior year.
• Other Non-Current Assets rose to $9.8 billion in Q1 2026, from $9.6 billion in the prior quarter.
• Over the last five years, Other Non-Current Assets for PFE reached as high as $13.2 billion in Q4 2022 and fell as low as $7.7 billion in Q3 2022.
• The 5-year median for Other Non-Current Assets is $9.8 billion (2025), against an average of $10.4 billion.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets soared 71.42% — and 2024, when it declined 21.28%.
• A 5-year view of Other Non-Current Assets shows it stood at $13.2 billion in 2022, then declined by 5.26% to $12.5 billion in 2023, then fell by 21.28% to $9.8 billion in 2024, then fell by 1.89% to $9.6 billion in 2025, then grew by 2.11% to $9.8 billion in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $9.8 billion, $9.6 billion, and $9.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.